| DB ID | MyCo_2940 |
| Title | The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy |
| Year | 2010 |
| PMID | 20713673 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The care of the rabbits was conducted according to the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care and the approved by the Animal Care and Use Committee of the National Cancer Institute. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | A well-described per- sistently neutropenic rabbit model of invasive pulmonary aspergillosis was used for all experiments. Briefly, female New Zealand White rabbits weighing 2.6 to 3.5 kg were used. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Acute invasive pulmonary aspergillosis is a leading cause of morbidity and mortality in immunocompromised patients. There have been considerable efforts to improve the diagnostic accuracy and therapeutic outcomes associated with this fre-quently lethal infection. A better understanding of the rela-tionship of clinically relevant biomarkers and the pathogenesis of invasive pulmonary aspergillosis would facilitate further de- velopment of strategies to identify and treat patients at the earliest possible time. |
| Technique | ELISA |
| Analysis Method | FDA Approved -Platelia Aspergillus Ag ELISA |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
